ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

1600 1067 Julien Ferrari, PharmD, PhD

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients.

You can find the original press release here.

Julien Ferrari, PharmD, PhD

All stories by:Julien Ferrari, PharmD, PhD
Brainwork is supported by unrestricted grants from: